

TITLE:	LONG-TERM SURVEILLANCE STUDY OF RITUXIMAB (MABTHERA)-TREATED PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA)
PROTOCOL NUMBER:	BE29950
PROTOCOL VERSION NUMBER:	2.2 (18th July 2018)
DATE OF LAST VERSION:	21 March 2016 (version 1.2)
AUTHOR:	<p>Chief Investigator ██████████ ██████████ Addenbrooke's Hospital, Cambridge, CB22QQ, UK Tel/Fax ██████████ ██████████</p> <p>Co-Investigator ██████████ ██████████ ██ ██████████ ██ Tel ██████████ Fax ██████████ ██</p>
EU PAS REGISTER NUMBER:	EUPAS16359
ACTIVE SUBSTANCE:	L01XC02: Rituximab
MEDICINAL PRODUCT:	MabThera®
PRODUCT REFERENCE NUMBER:	EMA/H/C/165
PROCEDURE NUMBER:	EMA/H/C/165/MEA/093
MARKETING AUTHORIZATION HOLDER (MAH):	Roche Registration GmbH Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Deutschland
MAH CONTACT PERSON:	██████████
RESEARCH QUESTION AND OBJECTIVES:	RIVAS is a secondary use of data study aimed to provide long-term safety data from the use of rituximab (MabThera) and other available therapies for patients with GPA or MPA. The primary objective of this study is to provide long-term safety data on rituximab (MabThera)-treated patients with GPA/MPA. The secondary objectives are (1) to estimate

	the incidence of serious adverse events (SAEs), including infections, cardiovascular events and malignancies, following rituximab or other available treatments in patients with GPA/MPA, and (2) to compare the incidence of each safety event over time between the rituximab (MabThera) cohort and the cohort treated with other available therapies.
COUNTRY OF STUDY:	United Kingdom

1. TABLE OF CONTENTS

1.	Table of contents.....	3
2.	List of abbreviations	4
3.	Responsible parties.....	5
4.	Abstract	6
5.	Amdements and updates	7
6.	Milestones	7
7.	Rationale and background	7
8.	Research question and objectives	11
9.	Research methods	11
9.1	Study design.....	11
9.2	Setting	12
9.3	Variables	12
9.4	Data sources and data management	13
9.5	Study size	14
9.6	Data analysis.....	14
9.7	Quality control	15
9.8	Limitations of the research methods	16
10.	Protection of human subjects.....	16
11.	Management and reporting of adverse events/adverse reactions.....	16
12.	Plans for disseminating and communicating study results	17
13.	References	18
	Appendix 1 – Data Collection Overview (as per Standard of Care)	19
	Appendix 2 – Draft Annual Safety Reporting Template	20
	Appendix 3 – ENCePP checklist for study protocols	24

2. LIST OF ABBREVIATIONS

AAV	ANCA-associated vasculitis
ANCA	Anti-neutrophil cytoplasmic antibody
BVAS	Birmingham Vasculitis Activity Score
CI	Confidence Interval
CYC	Cyclophosphamide
EMA	European Medicines Agency
EU	European Union
FDA	Food and Drug Administration
GFR	Glomerular filtration rate
GPA	Granulomatosis with polyangiitis
GVP	Guideline on good pharmacovigilance practices
CHMP	Committee for Medicinal Products for Human Use
IgG	Immunoglobulin G
MAH	Marketing Authorisation Holder
MPA	Microscopic polyangiitis
NIPASS	non-interventional post-authorization safety study
PBRER	Periodic Benefit Risk Evaluation Report
PI	Principal Investigator
RIVAS	Rituximab surveillance study in VASculitis
RMP	Risk Management Plan
UKIVAS	The UK and Ireland vasculitis registry
SAE	Serious Adverse Event
VDI	Vasculitis Damage Index

3. RESPONSIBLE PARTIES

Chief Investigator

[REDACTED]

Vasculitis office, [REDACTED] Addenbrooke's Hospital, Cambridge, CB22QQ, UK

Tel/Fax [REDACTED]

[REDACTED]

Clinical Research Assistant

[REDACTED]

Vasculitis Research, [REDACTED]

Cambridge University Hospitals NHS Foundation Trust

Addenbrookes Hospital Hills Road, Cambridge CB2 0QQ

[REDACTED]

Co-Investigator

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Tel [REDACTED] Fax [REDACTED]

[REDACTED]

4. ABSTRACT

Rituximab (MabThera) is a licensed therapy for the induction of remission in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). There is a paucity of data on the long term safety of rituximab (MabThera) for this indication. The UK and Ireland vasculitis registry (UKIVAS) is a nation-wide independent registry collecting long-term observational data on patients with vasculitis across 27 sites. The vasculitis clinic at Addenbrooke's Hospital Cambridge UK is one of the 27 UKIVAS centers providing data into UKIVAS, data of which will be used for the Rituximab (MabThera) surveillance study in VASculitis (RIVAS).

RIVAS includes all GPA/MPA patients who received rituximab (MabThera) in Cambridge at any time since 2003 (approx. 200 cases) and all GPA/MPA patients treated with other agents (approx. 200 cases).

An annual data set will be extracted from the UKIVAS database (hosted in Oxford, UK) to include the following:

- Serious adverse events – including patient and renal survival, hospitalization, infections
- Other events including cardiovascular events – malignancies, vasculitis relapse, cumulative 'all cause' damage
- Concomitant therapy
- Lab abnormalities: neutropaenia and hypogammaglobulinaemia.

The Addenbrooke's Hospital Cambridge UK will retrospectively analyze the extracted data and provide an annual report with aggregated safety data to the Marketing Authorisation Holder (MAH), which will be submitted to the European Medicines Agency (EMA) through the Periodic Benefit Risk Evaluation Report (PBRER).

5. AMENDMENTS AND UPDATES

Milestone, data analysis and SAP sensitivity analysis updated. MAH and study team updates. Clarification of data/event data collection period being from time of first rituximab (Mabthera) exposure to defined end of data collection date as specified in Milestone section. Clarification of collection of data following rituximab (MabThera) biosimilar exposure. Clarification of exclusion criteria based on the routine use of biosimilars since first approval.

6. MILESTONES

Study milestones are given in the following table.

Milestone	Planned Date
Start of study	1 month after CHMP approval
End of patient inclusion (i.e. the last date that a patient will receive study drug)	30 September 2017
End of data collection for any patient, regardless of the date of patient consent	30 September 2018
End of study	As soon as all eligible patients are consented and data extraction is complete
First cumulative report by PI to MAH	October 2016
First cumulative report in PBRER	January 2017
Second cumulative report by PI to MAH	October 2017
Second cumulative report in PBRER	January 2018
Third cumulative report by PI to MAH	October 2018
Third cumulative report in PBRER	January 2019
Fourth cumulative report by PI to MAH	October 2019
Fourth cumulative report in PBRER	January 2020
Registration in the EU PAS register	23 November 2016
Final report of study results*	31 December 2021

* The final report will replace the fourth cumulative report if needed

7. RATIONALE AND BACKGROUND

GPA and MPA are the two major forms of systemic vasculitis associated with the presence of ANCA [1]. These conditions are termed ANCA-associated vasculitis (AAV) because of their strong association with highly specific autoantibodies. AAV encompasses autoimmune disorders in which tolerance for one of two self-antigens, proteinase 3 (PR3) or myeloperoxidase (MPO), has been lost,

leading to the production of PR3- or MPO ANCA. Animal models, in vitro experiments, and many clinical observations in humans suggest that endothelial injury and tissue damage are dependent upon the pro inflammatory effects of ANCA that result from the interaction of these specific antibodies with their target antigens on the surface of activated neutrophils and monocytes.

The prognosis for untreated GPA is poor with a low likelihood of survival (much less remission) in the absence of conventional treatment with cyclophosphamide (CYC) [2]. Regimens involving CYC and high doses of glucocorticoids have led to successful control of the disease and, in most cases, the prevention of death from overwhelming AAV [3,4,5]. Current available therapies are associated with significant toxicities, as well as disease relapses when therapy is tapered or discontinued, and therefore novel and targeted mechanism-based treatment approaches are needed. There is strong support for a crucial role for B lymphocytes in the pathogenesis of GPA and MPA [4,6,7] and, therefore, a clear rationale for the use of a B-cell depleting therapy such as rituximab.

This rationale led to the first published account of RTX therapy in an AAV patient (Specks et al. 2001). Subsequent investigator-initiated studies (Eriksson 2005; Keogh et al. 2005, 2006; Omdal et al. 2005; Aries et al. 2006; Smith et al. 2006; Stasi et al. 2006; Brihaye et al. 2007; Sanchez-Cano et al. 2008; Seo et al. 2008; Jones et al. 2009; Lovric et al. 2009) have demonstrated induction of remission in severe and often refractory patients.

Rituximab has been investigated in one multi-center, active-controlled, non-inferiority trial of rituximab vs CYC (RAVE) [8], as well as in a number of smaller investigator-initiated studies and case series (Appendix 8). Results of the RAVE study support the conclusion that rituximab is non-inferior to CYC over 6 months of treatment; a higher percentage of patients in the RTX arm (64%) achieved complete remission at 6 months compared with patients in the CYC arm (55%). The lower limit of the 95.1% CI for the absolute difference, - 4.3%, was greater than the non-inferiority margin of -20% and thus met the protocol-specified non-inferiority criterion. Non-inferiority to CYC was observed consistently across secondary and exploratory endpoint and across subgroups defined by demographic and disease characteristics. At 18 months, efficacy findings were similar to those observed at 6 months. The proportion of patients who maintained their complete remission at 12 months and 18 months was similar across treatment groups.

Overall tolerability at 6 months was comparable between RTX and CYC treatment in RAVE: the proportions of patients experiencing any AE, any severe (Grade \geq 3) AE, or any serious AE were similar between the RTX and CYC groups, as were the overall rates of any AE and serious AE per patient-year. The most frequently reported type of AE and serious AE were infections, comprising most commonly upper respiratory tract infections. The incidence of these and other events of special interest for rituximab, such as serious cardiac adverse events and malignancies, were similar across treatment groups over 6 months of treatment. No serious IRRs were reported. The overall profile of adverse events reported over 18 months and out to the common closeout date of RAVE was similar

to that observed at 6 months. The rates (95% CI) of malignancy in the RTX and CYC groups were 2.00 (0.90–4.46) and 0.73 (0.18–2.91) per 100 patient-years, respectively. Overall, however, rates of death, serious infection, and malignancy were within those expected for AAV populations. Safety events in the investigator-initiated studies reported in the literature are limited. However, these data are generally consistent with those reported in the RAVE study. The most common type of adverse event reported was infection, particularly respiratory infection.

Based on the results from RAVE study, rituximab (MabThera) was licensed for the induction of remission for patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) by the FDA in 2011 and the EMA in 2013. The MabThera CHMP Type II variation assessment report for GPA/MPA application (EMA/H/C/165/II/79) requires that long-term safety in GPA/MPA patients, which is identified in the Risk Management Plan (RMP) as missing information, should be addressed via data from identified EU registries and should be included in the next version of the RMP as an additional pharmacovigilance activity. The MAH will fulfill this RMP commitment by collaborating with one of the centers within UKIVAS to obtain aggregated long-term safety data in GPA/MPA patients.

This proposed observational pharmacovigilance study aims to better characterize the risk profile of rituximab (MabThera) by collecting safety-focused data in patients with GPA/MPA who have been treated with rituximab (MabThera) or other available therapies. The study is a European Medicines Agency (EMA) post-authorization commitment and represents a non-interventional post-authorization safety study (NI-PASS, as defined by Directive 2001/83/EC [DIR] Art 1[15], E.U. Pharmacovigilance Legislation, and the Guideline on Good Pharmacovigilance Practice Module VIII).

The UK and Ireland vasculitis registry (UKIVAS) is a national independent registry collecting long term observational data on patients with vasculitis. This registry had its early origins in the “Lockwood Club” which was a pioneering vasculitis study group established in 1995 by Dr Martin Lockwood (Cambridge), Dr David GI Scott (Norwich), and Dr Richards Watts (Ipswich). Since then the club has grown in size and scope and is now UKIVAS. The Vasculitis Rare Disease Group evolved from UKIVAS, a steering group set up to develop the national Vasculitis registry. Its aims are

- to create a database of Vasculitis patients in the British Isles
- to build-up longitudinal clinical data to create a picture of the patient's clinical course
- to link the clinical information to biological samples

This will enable large-scale genetics and epidemiology studies, identify cohorts of patients to recruit for clinical trials and biomarker studies, allow multi-centre audit of novel biological therapies and inform logical service delivery. There are currently 27 UK and Ireland sites involved in enrolling patients in the UKIVAS database. The registry is curated in Oxford UK by Raashid Luqmani and has an established clinical governance system supervised by a management committee chaired by Mark Little (Dublin) and Richard Watts (Ipswich).

The vasculitis clinic at Addenbrooke's Hospital Cambridge UK is one of the 27 UKIVAS centers. It was established in 1987 and currently cares for over 400 patients with GPA/MPA. The center in Cambridge has led studies of rituximab in GPA/MPA since 2003. Data from the Addenbrooke's Hospital submitted to the UKIVAS will be the data source for the rituximab (MabThera) surveillance study in VASculitis (RIVAS).

8. RESEARCH QUESTION AND OBJECTIVES

Research question

RIVAS is a secondary use of data study aimed to provide long-term safety data from the use of rituximab (MabThera) and other available therapies for patients with GPA or MPA.

Objectives

The primary objective of this study is:

- To provide long-term safety data on rituximab ((MabThera)-treated patients with GPA/MPA.

The secondary objectives are:

- To estimate the incidence of serious adverse events (SAEs), including infections, cardiovascular events and malignancy, following rituximab (MabThera) or other available treatments in patients with GPA/MPA
- To compare the incidence of each safety event over time between the rituximab (MabThera) - treated cohort and the cohort treated with other available therapies

9. RESEARCH METHODS

9.1 Study design

This study is a non-interventional secondary data safety study in patients with GPA/MPA exposed to rituximab (MabThera) or other available treatments as part of their standard clinical care. Data will be extracted from the Cambridge site within UKIVAS database. Patients in each treatment cohort (rituximab (MabThera) or other available treatment regimens) will be followed from time of disease flare or or disease diagnosis since 2003 (year of first use of rituximab (MabThera) in Cambridge, estimate 200 per group, total 400). Patients who switch treatment regimens during the course of their registry follow-up will continue to be followed with date of switching recorded. Data will be extracted to the end of study, loss to follow-up or to withdrawal of consent or death and will be evaluated and patients treated according to physician's standard practice.

AAV patients with minimum disease duration of six months attending the Cambridge Vasculitis Clinic will be invited to participate. Potential patients will be given a study participant's information sheet to read, prior to signing informed consent once any of their questions have been satisfactorily answered by the study team. Study data, reflecting safety events occurring within duration of study, will be collected as per Appendix 1. Immunosuppressive, rituximab (MabThera) and glucocorticoid exposure will be calculated from date of diagnosis (Section 9.3) to date of assessment using data derived from the hospital patient record. The rituximab (MabThera) group will comprise patients who have received rituximab (MabThera) at any time since diagnosis of GPA/MPA. The control group will comprise patients who have never received rituximab (MabThera). In the event they were included in the

control group, patients receiving rituximab (MabThera) a after being treated with other treatments will cease to be included in the control group and will move to the rituximab (MabThera) group. Aggregated summary results will be prepared by the PI every 12 months and submitted to the MAH.

9.2 Setting

Patients must meet the following criteria for study entry:

- Clinical diagnosis of GPA/MPA through use of the consensus algorithm for the classification of ANCA vasculitis and polyarteritis nodosa (European Medicines Agency, Abdulkader et al 2013)
- Age \geq 18 years
- Have given informed consent to participate in the UKIVAS registry
- Have given informed consent to participate in the RIVAS study
- Any patient with GPA/MPA who has received rituximab (MabThera) for vasculitis since 2003 (rituximab (MabThera) group)
- Any GPA/MPA patient with disease flare since 2003 who has not received rituximab (disease control group)

Patients who meet any of the following criteria will be excluded from study entry:

- Patients with eosinophilic granulomatosis with polyangitis (EGPA/Churg-Strauss)
- Unwilling or unable to provide written informed consent for the UKIVAS registry
- Unwilling or unable to provide written informed consent for the RIVAS study

Patients with significant concomitant disease (e.g. cancer, HIV/AIDS) will not be excluded from the study. Significant concomitant diseases will be considered at the analysis stage.

9.3 Variables

Primary variables

- Baseline demography
 - Diagnosis GPA or MPA
- Status at time of evaluation
 - Date of rituximab (MabThera) administration
 - Onset date of event
 - Occurrence of serious adverse events (SAE) in last 6 months
 - Type of event (MedDRA code)
 - Outcome of event
 - All malignancies in the last 6 months

Secondary variables

- Baseline demography
 - Age, gender, ethnicity (Caucasian Y/N)
 - Height and weight
 - ANCA at diagnosis (PR3-ANCA/ MPO-ANCA or ANCA negative)
 - Date of diagnosis
 - Drug exposure
 - Cyclophosphamide, g
 - Glucocorticoids, months
 - Prior azathioprine, methotrexate or mycophenolate
 - Number and type of other immunosuppressives
 - Co-morbidities (cardiovascular disease, chronic pulmonary disease, malignancy, diabetes)
- Status at time of evaluation
 - Vasculitis activity
 - Disease state (active/remission/low disease activity state)
 - Severe disease flare (one or more BVAS/WG new/worse 'major' items) over past 6 months
 - GFR, IgG, CD19 count (if measured), neutrophil count (if measured)
 - Pregnancy and contraception status (for women of childbearing potential) (if available)
 - Concomitant glucocorticoid and immunosuppressive therapy
 - Occurrence of lab abnormalities (neutrophil count $< 1.5 \times 10^9$ /L, IgG $< 3\text{g/L}$ and $< 5\text{g/L}$, in last 6 months (note: lab abnormalities will be reported as adverse events if treatment is required or treatment has been changed)
 - Vasculitis Damage Index (VDI)

Information will be collected as per local standard of practice.

9.4 Data sources and data management

All data included in RIVAS are obtained by the investigational site and entered in the UKIVAS registry. MAH does not have any influence in the data collection nor the registry design. MAH will not receive any patient-level data nor have direct access to registry data. RIVAS will include data from all GPA/MPA patients who have received rituximab (MabThera) in Cambridge at any time since 2003 (approx. 200 cases) and all GPA/MPA patients treated with other agents (approx. 200 cases). There will be no patient selection (see 9.1). Data collection commences at the time of enrolment into UKIVAS and continues every 6 months. Data may be supplemented by extracting data recorded prior to baseline and between patient visits. All baseline data, and event data between assessment time points, will be derived from information routinely collected in the Hospital Patient Record with the exception of VDI, which will be scored at the six monthly visit. The investigational site will be

responsible for management of the data they collect, including quality checking of the individual data points. Aggregate data reports will be transferred to the MAH at annual intervals as specified in the Statistical Analysis Plan. Patient confidentiality will be respected and all data transmitted to the registry will be anonymous. Quality control will be achieved by back checking periodically from the UKIVAS registry against a sample of primary data sheets (See Section 9.7).

9.5 Study size

All patients with GPA/MPA who are managed by the Vasculitis and Lupus Clinic at Addenbrooke's Hospital, Cambridge, U.K., who fulfill the eligibility criteria, and who have received rituximab (MabThera) or other available treatments during the study period will be invited to participate without further restrictions. A formal study size calculation has therefore not been performed.. Patients are followed to the end on the observational period, a mean of 2.5 years with a range of 0.5 to 5 years. A previous long-term follow-up study of rituximab (MabThera) treated AAV patients from Cambridge reported serious adverse events occurring in 37%, and infections occurring in 24%, of patients treated with rituximab (MabThera) over a mean follow-up period of 104 months. A sample size of approximately 200 patients per group is expected.

9.6 Data analysis

The Principal Investigator will retrospectively analyze a pre-specified data-cut within the Cambridge center every 12 months for the cumulative study report. For each patient cohort, variables will be summarized using mean, median, standard deviation and range for continuous data, and counts and percentages for categorical data.

Following the methodology used in rheumatoid arthritis, two main analytical approaches will be used depending on the outcome of interest. For analyses of risk of malignancy, the primary analysis will use an ever-exposed model that includes all person-time since the first drug dose in the study. For all SAEs except malignancy, the primary analysis will be based on a time-on-drug approach that uses a pre-defined risk window after the last administration of rituximab (MabThera) or other available therapies. An outcome of interest occurring during the defined risk window period will be allocated to the preceding treatment identically for both drug regimens. Details of how the study will account for treatment switching can be found in the Statistical Analysis Plan (SAP).

Sensitivity analyses will be performed to assess how dependent the conclusions are to the methods and assumptions used to deal with switching. The sensitivity analyses will include, but not be limited to: varying the duration of the risk windows; censoring at the first switch (in both drug regimens); and down-weighting observations from switchers. All methods of analysis will be systematically applied to each event definition.

The analysis of the primary endpoint will be stratified by enrolment period (pre-consent versus post-consent) to assess robustness of conclusions from primary analysis due to change in study design.

The PI will provide yearly cumulative study reports with aggregated data on safety events that occur in each patient cohort. The total number of safety events and unadjusted incidence rates per 1000 patient-years and 95% confidence intervals (CIs) will be provided for each patient cohort, as well as for males and females within each cohort (Appendix 2). Incidence rates will be calculated using Poisson regression model and the CI provided, assuming the estimated parameters follow a normal distribution.

In addition to these yearly study reports, the PI will provide a final report at the end of data extraction and analysis. The study final report will also contain event rates per 1,000 patient-years and 95% CIs: First, event rates including all events reported within the qualifying exposure window will be presented, assuming that the inter-event time observations are exchangeable within patients, and do not depend on the number of times the event has recurred within a patient. The rates will then be represented using first events only, censoring at first switching. Subsequent recurrent events will be summarized by presenting Kaplan-Meier curves for the time from 1st to 2nd event, and generally the time from nth to (n+1)th event, until the number of events falls below 10; the times will be censored at the first switching, and survival curves provided separately for the two drug regimens.

The hazard ratio between the rituximab (MabThera) and control group (males and females combined) with associated 95% CIs will be estimated using Cox-proportional hazards models. Patients (in both cohorts) are enrolled over a period of time and the study will end on a specific calendar date. Thus, patients who enroll later will be followed/observed for a shorter period than patients who enroll early. Also, some patients may drop out of the study before the end of study and others may die. Therefore the time-to-event analyses, e.g. Cox regression model, where patients without an event of interest will be censored at the last date known to be followed-up, will be applied. A comparison will only be made only when a minimum of 10 events across both groups has been observed with at least one event in each cohort. Unadjusted and adjusted hazard ratios will be presented, taking into account potential confounders, including age, disease duration, ANCA type, co-morbidities (eg, diabetes, cardiac disease, malignancy, pulmonary disease), etc. Subgroup analyses will be performed according to specific co-morbidities and categories of VDI. The extended Cox Proportional Hazard Model will be used to account for treatment switching.

Full details of planned statistical summaries including mapping of the adverse events, treatment switching and adjusted analysis will be specified in a Statistical Analysis Plan which will be developed before the first annual report.

9.7 Quality control

Serious adverse event episodes will be notified to the study team when they occur. In addition, the occurrence of any episodes in the previous six months will be recorded from the routine visits. Where there is a discrepancy in notification a query will be raised by the study team and the hospital charts examined.

9.8 Limitations of the research methods

This observational, longitudinal, non-interventional study design aims to evaluate the risk profile of rituximab and other available treatment regimens in patients with either GPA or MPA in a real-world setting. Choice of therapy is at the discretion of the treating physician and this may introduce selection bias which that could lead to an imbalance of baseline patient demographics and/or confounding variables between treatment cohorts. It is possible that patients with GPA or MPA who participate in this single-center study may not be representative of the population as a whole, however, both indications are relatively rare and this may mitigate any lack of representativeness. The statistical methods used in the generation of the interim and final report provided to the MAH are intended reduce the possibility of the introduction of bias or error into the findings by adjusting for baseline covariates and potential confounders. Nevertheless, residual bias could still persist due to unmeasured or imprecisely measured confounding factors.

10. PROTECTION OF HUMAN SUBJECTS

Patients are treated according to the principles decided by the responsible physician, not influenced by the study. Patient confidentiality will be respected and all data transmitted to the registry will be anonymous. MAH will not receive any patient-level data nor have direct access to registry data. All patient data will be submitted into the UKIVAS registry after written informed consent by the patient. The registry operates under relevant ethical approvals from the United Kingdom and Ireland.

11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS

The GVP Module VI – Management and Reporting of Adverse Reactions to Medicinal Products (EMA, 2012) distinguishes between non-interventional studies that are based on primary data collection directly from consumers and HCPs and study designs that are based on the secondary use of data, such as the use of data from existing registries.

EMA GVP Module VI states that

“For non-interventional study designs which are based on secondary use of data, adverse reactions reporting is not required. Reports of adverse events/reactions should only be summarised in the study report, where applicable” (EMA, 2012, section VI.C.1.2.1.).

Therefore, the responsibility for adverse event reporting will remain with the treating physician. The MAH will receive only anonymized aggregated data from the registry, which will be summarized in the annual and overall final study reports.

12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

The MAH will review all study reports and then submit them to the Health Authorities through the PBRER. Results might be published by the PI independently of Roche.

13. REFERENCES

1. Hoffman GS and Specks U. Antineutrophil Cytoplasmic Antibodies. *Arthritis & Rheuma* 1998; 41(9):1521-1537.
2. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). *Br Med J* 1958;2(5091):265–70.
3. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. *Medicine* 1973;52(6):535–61.
4. Fauci AS, Dale DC, Wolff SM. Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis. *Arthritis Rheum* 1974;17(4):355–61.
5. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116(6):488–98.
6. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. *N Engl J Med* 1971;285(27):1493–6.
7. Wolff SM, Fauci AS, Horn RG, et al. Wegener's granulomatosis. *Ann Intern Med* 1974;81(4):513–25.
8. Clinical Study Report: Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis. Report no CSR ITN021A1. September 2010.

Appendix 1 - Data Collection Overview (as per Standard of Care)

Data Collection (available data will be collected, no additional diagnostic or monitoring procedures shall be applied to the patients outside routine clinical practice)	Screening and/or baseline visit ^a	Every 6-Month (±45 days) Data Collection ^b	Early Termination	Non-Enrolled, Eligible Patients
Informed consent for UKIVAS ^c	x			
Review patient eligibility (inclusion/exclusion criteria)	x			
Demographic data ^d	x			x
Date diagnosis of GPA/MPA	x			
Previous GPA/MPA treatment	x	x	x	
Co-morbidities	x			
Current GPA or MPA disease status ^f	x	x		
Vasculitis Damage Index (VDI)	x	x		
GFR, neutrophil count, IgG, CD19 (if measured)	x	x		
Current medication	x	x		
Occurrence of severe flare since last data collection time point ^g	x	x		
Height and weight ^h	x	x		
Pregnancy status (if available)	x	x		
SAEs	x	x	x	
Malignancies, including NMSC	x	x	x	
Laboratory abnormalities - Neutrophil count <1.5 x 10 ⁹ /L, IgG < 3g/L (if measured)	x	x	x	
Reason for early termination			x	

^a Screening and baseline visits may be performed on the same day

^b Patients will be evaluated and treated according to their physician's standard practice and discretion at their standard-of-care visits. Data will be collected every 6 months (± 60 days) from patients' medical records. All data collection dates should be projected on the basis of the date of the patient's baseline office visit.

^c Written informed consent must be obtained before any data collection.

^d Patient demographic information includes the collection of date of birth, sex, and race/ethnicity

^e Record the reason the patient did not enroll, the dose of RTX prescribed, and concomitant GPA or MPA therapy, if any.

^f Provide the details of tests and information collected (including renal involvement)

^g defined as one or more new/worse 'major' items on the BVAS/WG

^h Height and weight will be recorded at screening/baseline visit. At all subsequent visits, only weight will be collected.

APPENDIX 2 – DRAFT ANNUAL SAFETY REPORTING TEMPLATE

The table shell below should be generated for each treatment cohort (ie, rituximab and other available treatment regimens)

Table 1 Patient Demographics

Start of observation		
Number of new registrations (dd.mm.yyyy to dd.mm.yyyy, dates to be determined)		
Cumulative number of registrations (since date of first registration)		
Cumulative number by gender	Male	
	Female	
Cumulative number by age at registration	18–29	
	30–39	
	40–49	
	50–64	
	65–74	
	≥ 75	

Table 2 Baseline Characteristics

					Mean			SD (not applicable for all variables)		
		GPA	MPA	Total	GPA	MPA	Total	GPA	MPA	Total
Age (years)	Male									
	Female									
	Total									
Clinical diagnosis (GPA/MPA, No/%)	Male									
	Female									
	Total									
Time since diagnosis (months)	Male									
	Female									
	Total									
Disease duration prior to first RTX infusion (months)	Male									
	Female									
	Total									
Ethnicity (Caucasian, No/%)	Male									
	Female									
	Total									
Vasculitis Damage Index (VDI)	Male									
	Female									
	Total									
Active vasculitis in last year (BVAS/WG \geq 1) (No/%)	Male									
	Female									
	Total									
ANCA type (PR3-ANCA, MPO-ANCA, ANCA negative, No/%)	Male									
	Female									
	Total									
Prior use of rituximab for GPA/MPA (No/%)	Male									
	Female									
	Total									
Rituximab exposure (g)	Male									
	Female									
	Total									
Time since first rituximab for GPA/MPA (months)	Male									
	Female									
	Total									
Prior exposure to CYC (g)	Male									
	Female									

					Mean			SD (not applicable for all variables)		
		GPA	MPA	Total	GPA	MPA	Total	GPA	MPA	Total
	Total									
Prior duration of glucocorticoids (months)	Male									
	Female									
	Total									
Prior exposure to azathioprine (No/%)	Male									
	Female									
	Total									
Prior exposure to methotrexate (No/%)	Male									
	Female									
	Total									
Prior exposure to a mycophenolate preparation (No/%)	Male									
	Female									
	Total									
Number of non-glucocorticoid immunosuppressives or non rituximab biologics (median)	Male									
	Female									
	Total									
GFR at time of first RTX (ml/min, median)	Male									
	Female									
	Total									
Proportion receiving ongoing glucocorticoids (No/%)	Male									
	Female									
	Total									
Proportion receiving ongoing non-glucocorticoid immunosuppressive or non-rituximab biologic (No/%)	Male									
	Female									
	Total									
Comorbidity * specificity	Male									
	Female									
	Total									

* Comorbidity defined as diabetes, cardiac disease, non-skin malignancy or chronic pulmonary disease occurring before first rituximab treatment

Table 3 Cumulative Listing and Incidence Rates of Adverse Events after RTX Infusion (or Other Treatment Depending on Patient Cohort)

Event	Males		Females		Total	
	Events (N)	Rate (95% CI)	Event (N)	Rate (95% CI)	Events (N)	Rate (95% CI)
Serious Infection						
Septicaemia						
HBV reactivation						
Herpes infection						
Opportunistic infection (including TB)						
Upper respiratory tract infections						
Lower respiratory tract infections						
Total Serious Infection						
Cardiovascular Disorders						

Event	Males		Females		Total	
	Events (N)	Rate (95% CI)	Event (N)	Rate (95% CI)	Events (N)	Rate (95% CI)
Congestive heart failure (new or worsening)						
Coronary artery disease						
Myocardial infarction						
Stroke (ischemic, haemorrhagic, or undetermined origin)						
Venous thrombotic event (DVT,PE)						
Cardiovascular death						
Other cardiovascular events (not mentioned above)						
Total cardiovascular disorders (any of above)						
Haematological Events						
Agranulocytosis						
Aplastic anaemia						
Neutropenia (ANC <1500 μ l) [†]						
Other dyscrasia						
Pancytopenia						
Thrombocytopenia						
Total haematologic events (any of above)						
Malignant Events						
Leukaemia						
Lymphoproliferative disorder						
Lymphoma (NHL, Hodgkin, diffuse large b-cell lymphoma (DLBCL))						
Myeloma						
Non-melanoma skin cancer						
Other malignant solid tumours						
Total malignant events (any of above)						
Renal Insufficiency						
End-stage renal disease (ESRD)						
Dialysis						
Plasma Exchange						
Renal transplantation						
Total renal insufficiency (any of above)						
Progressive multifocal leukoencephalopathy						
PML						

Event	Males		Females		Total	
	Events (N)	Rate (95% CI)	Event (N)	Rate (95% CI)	Events (N)	Rate (95% CI)
Additional Safety Events						
Serious disease flares i.e major flare						
Serious infusion-related reaction						
Gastrointestinal perforation						
Hypogammaglobulinemia (<300 mg/dL) [†]						
Hypogammaglobulinemia requiring IVIg replacement						
Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis (confirmed by skin biopsy)						
All SAEs leading to treatment discontinuation						
Pregnancy						
Vaccination failure						
Posterior reversible encephalopathy syndrome (PRES) or Reversible progressive leukoencephalopathy syndrome (RPLS)						
Any SAEs occurring in either mother, foetus, or baby following exposure of the mother						
Death (all cause)						
All SAEs (any of the above)						

[†] lab abnormalities will be reported as adverse events if treatment is required or treatment has been changed)

Table 4 Cumulative Listing and Incidence Rates of Lab abnormalities after RTX Infusion (or Other Treatment Depending on Patient Cohort)

Lab abnormalities	Males		Females		Total	
	Events (N)	Rate (95% CI)	Event (N)	Rate (95% CI)	Events (N)	Rate (95% CI)
Neutropenia (ANC <1500µl)						
Hypogammaglobulinemia (<300 mg/dL)						
Immunoglobulin G (<5g/l)						
Immunoglobulin G (<3g/l)						

APPENDIX 3 – ENCEPP CHECKLIST FOR STUDY PROTOCOLS



Doc.Ref. EMEA/540136/2009

ENCePP Checklist for Study Protocols (Revision 2, amended)

Adopted by the ENCePP Steering Group on 14/01/2013

The [European Network of Centres for Pharmacoepidemiology and Pharmacovigilance \(ENCePP\)](#) welcomes innovative designs and new methods of research. This Checklist has been developed by ENCePP to stimulate consideration of important principles when designing and writing a pharmacoepidemiological or pharmacovigilance study protocol. The Checklist is intended to promote the quality of such studies, not their uniformity. The user is also referred to the [ENCePP Guide on Methodological Standards in Pharmacoepidemiology](#) which reviews and gives direct electronic access to guidance for research in pharmacoepidemiology and pharmacovigilance.

For each question of the Checklist, the investigator should indicate whether or not it has been addressed in the study protocol. If the answer is "Yes", the page number(s) of the protocol where this issue has been discussed should be specified. It is possible that some questions do not apply to a particular study (for example in the case of an innovative study design). In this case, the answer 'N/A' (Not Applicable) can be checked and the "Comments" field included for each section should be used to explain why. The "Comments" field can also be used to elaborate on a "No" answer.

This Checklist should be included as an Annex by marketing authorisation holders when submitting the protocol of a non-interventional post-authorisation safety study (PASS) to a regulatory authority (see the [Guidance on the format and content of the protocol of non-interventional post-authorisation safety studies](#)). Note, the Checklist is a supporting document and does not replace the format of the protocol for PASS as recommended in the Guidance and Module VIII of the Good pharmacovigilance practices (GVP).

Study title:

Long-term surveillance study of rituximan (MabThera)-treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

Study reference number:

[The EU PAS registry number will be added after registration]

Section 1: Milestones	Yes	No	N/A	Page Number(s)
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection ¹	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7
1.1.2 End of data collection ²	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7

¹ Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.

² Date from which the analytical dataset is completely available.

<u>Section 1: Milestones</u>	Yes	No	N/A	Page Number(s)
1.1.3 Study progress report(s)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7
1.1.4 Interim progress report(s)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7
1.1.5 Registration in the EU PAS register	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7
1.1.6 Final report of study results.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7

Comments:

--

<u>Section 2: Research question</u>	Yes	No	N/A	Page Number(s)
2.1 Does the formulation of the research question and objectives clearly explain:				
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10
2.1.2 The objective(s) of the study?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-11
2.1.4 Which formal hypothesis(-es) is (are) to be tested?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
2.1.5 If applicable, that there is no <i>a priori</i> hypothesis?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10

Comments:

There is no *a priori* hypothesis, as randomised control trials did not report any significant differences in safety profiles between rituximab and comparator arm. (Stone et al. N Engl J Med. 2010; 363(3): 221–232)

<u>Section 3: Study design</u>	Yes	No	N/A	Page Number(s)
3.1 Is the study design described? (e.g. cohort, case-control, randomised controlled trial, new or alternative design)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-11
3.2 Does the protocol specify the primary and secondary (if applicable) endpoint(s) to be investigated?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-12
3.3 Does the protocol describe the measure(s) of effect? (e.g. relative risk, odds ratio, deaths per 1000 person-years, absolute risk, excess risk, incidence rate ratio, hazard ratio, number needed to harm (NNH) per year)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10, 13-14

Comments:

--

<u>Section 4: Source and study populations</u>	Yes	No	N/A	Page Number(s)
4.1 Is the source population described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-11
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-12

<u>Section 4: Source and study populations</u>	Yes	No	N/A	Page Number(s)
4.2.2 Age and sex?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12
4.2.3 Country of origin?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-12
4.2.4 Disease/indication?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-12
4.2.5 Co-morbidity?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12
4.2.6 Seasonality?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11-13

Comments:

--

<u>Section 5: Exposure definition and measurement</u>	Yes	No	N/A	Page Number(s)
5.1 Does the protocol describe how exposure is defined and measured? (e.g. operational details for defining and categorising exposure)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	12-13
5.2 Does the protocol discuss the validity of exposure measurement? (e.g. precision, accuracy, prospective ascertainment, exposure information recorded before the outcome occurred, use of validation sub-study)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10,12-13
5.3 Is exposure classified according to time windows? (e.g. current user, former user, non-use)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14
5.4 Is exposure classified based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.5 Does the protocol specify whether a dose-dependent or duration-dependent response is measured?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 6: Endpoint definition and measurement</u>	Yes	No	N/A	Page Number(s)
6.1 Does the protocol describe how the endpoints are defined and measured?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10, 13-14
6.2 Does the protocol discuss the validity of endpoint measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, prospective or retrospective ascertainment, use of validation sub-study)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-12

Comments:

--

<u>Section 7: Confounders and effect modifiers</u>	Yes	No	N/A	Page Number(s)
7.1 Does the protocol address known confounders? (e.g. collection of data on known confounders, methods of controlling for known confounders)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11-14

Section 7: Confounders and effect modifiers	Yes	No	N/A	Page Number(s)
7.2 Does the protocol address known effect modifiers? (e.g. collection of data on known effect modifiers, anticipated direction of effect)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11-14

Comments:

--

Section 8: Data sources	Yes	No	N/A	Page Number(s)
8.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
8.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview, etc.)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-13
8.1.2 Endpoints? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics, etc.)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-13
8.1.3 Covariates?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10-13
8.2 Does the protocol describe the information available from the data source(s) on:				
8.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11-13
8.2.2 Endpoints? (e.g. date of occurrence, multiple event, severity measures related to event)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11-13
8.2.3 Covariates? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, life style, etc.)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11-13
8.3 Is a coding system described for:				
8.3.1 Diseases? (e.g. International Classification of Diseases (ICD)-10)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11
8.3.2 Endpoints? (e.g. Medical Dictionary for Regulatory Activities (MedDRA) for adverse events)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11
8.3.3 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11
8.4 Is the linkage method between data sources described? (e.g. based on a unique identifier or other)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

--

Section 9: Study size and power	Yes	No	N/A	Page Number(s)
9.1 Is sample size and/or statistical power calculated?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

All patients with GPA/MPA who are managed by the Vasculitis and Lupus Clinic at Addenbrookes Hospital, Cambridge, U.K., who fulfill the eligibility criteria, and who have received rituximab or other available treatments during the study period will be invited to participate without further restrictions.

<u>Section 10: Analysis plan</u>	Yes	No	N/A	Page Number(s)
10.1 Does the plan include measurement of excess risks?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14
10.2 Is the choice of statistical techniques described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14
10.3 Are descriptive analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14
10.4 Are stratified analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14
10.5 Does the plan describe methods for adjusting for confounding?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14
10.6 Does the plan describe methods addressing effect modification?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 11: Data management and quality control</u>	Yes	No	N/A	Page Number(s)
11.1 Is information provided on the management of missing data?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6
11.3 Are methods of quality assurance described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
11.4 Does the protocol describe possible quality issues related to the data source(s)?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
11.5 Is there a system in place for independent review of study results?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13-14

Comments:

--

<u>Section 12: Limitations</u>	Yes	No	N/A	Page Number(s)
12.1 Does the protocol discuss:				
12.1.1 Selection biases?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
12.1.2 Information biases? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
12.2 Does the protocol discuss study feasibility? (e.g. sample size, anticipated exposure, duration of follow-up in a cohort study, patient recruitment)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13
12.3 Does the protocol address other limitations?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14

Comments:

--

<u>Section 13: Ethical issues</u>	Yes	No	N/A	Page Number(s)
13.1 Have requirements of Ethics Committee/Institutional Review Board approval been described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15
13.2 Has any outcome of an ethical review procedure been addressed?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15
13.3 Have data protection requirements been described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15

Comments:

--

<u>Section 14: Amendments and deviations</u>	Yes	No	N/A	Page Number(s)
14.1 Does the protocol include a section to document future amendments and deviations?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7

Comments:

--

<u>Section 15: Plans for communication of study results</u>	Yes	No	N/A	Page Number(s)
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15
15.2 Are plans described for disseminating study results externally, including publication?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	15

Comments:

--

Name of the main author of the protocol: ██████████ Addenbrooke's Hospital Cambridge UK

Date: 26/10/2015

Signature: _____